Key result
High-calcium PD solution linked to ~17% higher PWV at six months vs low-calcium.
Why the study?
Arterial stiffness is a key contributor to cardiovascular disease in dialysis patients, but the impact of dialysate calcium content on arterial stiffness progression is unclear.
Does high-calcium peritoneal dialysis solution increase arterial stiffness compared to low-calcium solution in peritoneal dialysis patients?
Cohort (n=49)
Does high-calcium peritoneal dialysis solution increase arterial stiffness compared to low-calcium solution in peritoneal dialysis patients?
Absolute Event Rate: 9.6% vs 8.2%
p-value: p=<0.05
Exposure to high-calcium peritoneal dialysis solutions may contribute to the progression of arterial stiffness in PD patients compared to low-calcium solutions.
High-calcium PD solutions may accelerate arterial stiffness; leaves open whether switching solutions improves outcomes in randomized trials.
BACKGROUND: One of the origins of cardiovascular disease in dialysis patients is arterial stiffness. The aim of our study was to assess the relationship between the calcium content of peritoneal dialysis (PD) solution and arterial stiffness. PATIENTS AND METHODS: We enrolled into the study 49 PD patients who had been treated with the same PD solution for the preceding 6 months. The calcium content of the PD solution was 1.25 mmol/L in 34 patients (low-Ca group) and 1.75 mmol/L in 15 patients (high-Ca group). Study patients were followed for 6 months on the same PD prescription. Arterial stiffness was assessed by measurement of augmentation index (AI) and brachial pulse wave velocity (PWV) at baseline and at month 6 (SphygmoCor: Atcor Medical, West Ryde, NSW, Australia). Demographic data were recorded from patient charts. RESULTS: Mean age of the whole group was 51 +/- 11 years, prevalence of diabetes was 14%, duration of PD was 43 +/- 30 months, percentage of women was 45%, and percentage of patients using a cycler was 33%. We observed no differences between groups with regard to those variables or creatinine clearance, residual renal function, Ca, phosphorus, parathormone, C-reactive protein, lipid parameters, and use of phosphate binder with or without Ca content. Mean arterial pressure was higher in the high-Ca group, but the difference was not statistically significant (100 +/- 22 mmHg vs 88 +/- 18 mmHg, p = 0.06). At baseline, AI was significantly higher in the high-Ca group than in the low-Ca group (27% +/- 10% vs 21% +/- 9%, p < 0.05). Measurements of PWV were not different between the groups (8.4 +/- 1.1 m/s vs 8.5 +/- 1.7 m/s). Measurement of arterial stiffness parameters at month 6 revealed that PWV had increased in the high-Ca group (to 9.6 +/- 2.3 m/s from 8.4 +/- 1.1 m/s, p < 0.05), but had not changed in the low-Ca group (to 8.2 +/- 1.9 m/s from 8.5 +/- 1.7 m/s). The AI did not change in either group. CONCLUSIONS: These data suggest that Ca exposure through PD solution plays a role in the progression of arterial stiffness, which may be related to increased vascular calcification.
No takes yet. Share an insight, caveat, or question.
Demirci et al. (2009) conducted a cohort in peritoneal dialysis (n=49). High calcium peritoneal dialysis solution vs. Low calcium peritoneal dialysis solution was evaluated on brachial pulse wave velocity (PWV) at 6 months (p=<0.05). Exposure to high-calcium peritoneal dialysis solution was associated with a significant increase in pulse wave velocity to 9.6 m/s at 6 months (p<0.05), whereas low-calcium solution was not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: